Drugging MYCN through an allosteric transition in Aurora kinase A
about
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseUbiquitin-Mediated Degradation of Aurora KinasesAurora Kinase Inhibitors: Current Status and OutlookTargeting the Mitotic Catastrophe Signaling Pathway in CancerScientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerOrigins, genetic landscape, and emerging therapies of small cell lung cancerA Cell Biologist's Field Guide to Aurora Kinase InhibitorsDrugging the addict: non-oncogene addiction as a target for cancer therapyExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerPseudokinases: update on their functions and evaluation as new drug targets.Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationDFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitorsA new role for an old enemy.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastomaN-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.Structural Basis for the Non-catalytic Functions of Protein Kinases.HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification.Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.Neuroblastoma treatment in the post-genomic era.A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Drugging the 'undruggable' cancer targets.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroTargeting MYC: is it getting any easier?Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Emerging Variants of Castration-Resistant Prostate Cancer.Family matters: How MYC family oncogenes impact small cell lung cancer.MYCN-targeting vaccines and immunotherapeutics.A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition.The structure of C290A:C393A Aurora A provides structural insights into kinase regulation.Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single-Molecule Spectroscopy.
P2860
Q24310764-5342C048-9352-44D6-BA82-471391AA7FA8Q26770280-BE2E8C02-0E0A-4EF6-9554-826890EBDF41Q26770583-09E6E7B1-A957-4BDD-820E-EAB648B55A64Q26778544-64F58511-B6E4-4B4F-9CD4-AC8807A2229CQ26784060-6D62253B-9A63-4D16-B8B1-FB8C595C81D3Q26798218-3B93DDA1-3F3B-4071-B26D-BF0E9FB6F5ECQ27308125-8011FB8A-8356-4498-B87A-285022EEE37BQ28079559-FD2054BB-4812-47FF-8E0A-1C047BBDB099Q28118450-2B55B4E8-0362-4A03-AD27-12B7EEC3A980Q28771715-4C4BC994-E9F5-4BB0-8126-83083A208044Q30397636-151A6EE6-7B7A-46C0-9484-85CBAD3F80A6Q31814812-75692BA3-0265-4B0F-9517-DDBE45DDF52EQ33430055-55B4F4DB-585C-42D9-B366-EF6649678488Q33566511-2CDA99A1-8071-45A9-9D5D-BEE087E4CF6BQ34992475-55DAF585-0472-49A0-8B94-48BA6ACE066FQ35111305-2D1178E5-EA9F-49E0-AD96-A8607D5021EFQ35819646-27159F2F-CA04-4631-AD66-38FF2AF91376Q35980945-33320BC6-A026-4940-AA2E-DD24FA1663B5Q36446161-EB694155-E550-46A0-B3B6-906656CED94BQ37387937-BE204FE8-02DC-4BC2-AAAF-7FE5BCD7808FQ37393746-232A1A0C-5DB8-4E81-AAAD-0B8293FADDE9Q37593293-195F3EE7-519A-4444-9C25-783F57CA4181Q37633731-27053FF1-3F43-4C14-8030-787A5153D921Q37672145-08F480FB-B284-4456-8DE8-7D893F60B055Q37688783-A18158F7-77B0-4E11-9607-17481BE66EF9Q37745480-96F979D8-F3D7-48D5-848D-27B6DC6B525AQ38294764-73120F6B-28D8-495D-9218-66D86154F0E0Q38539670-9A6AAA9E-F2D0-43A3-BBEA-BD3D7E65DB61Q38667658-D836D3CE-9BC0-4717-9154-304D8E15E1FEQ38730798-91790B97-4362-47EB-8B88-C085BBC2E444Q38819081-B63E94CC-A672-4100-B3A4-B9C829AB0EDCQ38894287-1959D3A8-D749-4FD9-8A0C-98231311083CQ38940139-BA8A616E-0F27-42BA-93EC-2341CFFC7F00Q39019412-6052B35B-FA83-4146-81F2-30EE3404BB65Q39210257-4CB5FC9E-A0CD-4198-AD05-451C562615B8Q39454070-54804961-E515-46C8-A63F-A588E9052CDFQ41118615-B9C8672E-2CBF-4163-B1B7-510BC11857A8Q42083680-884AB5A2-28BD-4ACD-B85A-CA4F8CED02F8Q42101067-C46A1FF4-43BB-43B3-B0E9-A7DDA5F89FEBQ42359642-C6895BC7-0E62-4D5D-8998-D1EDDCF0A8C7
P2860
Drugging MYCN through an allosteric transition in Aurora kinase A
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Drugging MYCN through an allosteric transition in Aurora kinase A
@ast
Drugging MYCN through an allosteric transition in Aurora kinase A
@en
Drugging MYCN through an allosteric transition in Aurora kinase A
@en-gb
Drugging MYCN through an allosteric transition in Aurora kinase A
@nl
type
label
Drugging MYCN through an allosteric transition in Aurora kinase A
@ast
Drugging MYCN through an allosteric transition in Aurora kinase A
@en
Drugging MYCN through an allosteric transition in Aurora kinase A
@en-gb
Drugging MYCN through an allosteric transition in Aurora kinase A
@nl
altLabel
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
@en
prefLabel
Drugging MYCN through an allosteric transition in Aurora kinase A
@ast
Drugging MYCN through an allosteric transition in Aurora kinase A
@en
Drugging MYCN through an allosteric transition in Aurora kinase A
@en-gb
Drugging MYCN through an allosteric transition in Aurora kinase A
@nl
P2093
P2860
P50
P3181
P1433
P1476
Drugging MYCN through an allosteric transition in Aurora kinase A
@en
P2093
Cyril Benes
Elise Charron
Erin A Nekritz
Justin Chen
Katherine K Matthay
Kevan M Shokat
Robert Seeger
William Clay Gustafson
P2860
P304
P3181
P356
10.1016/J.CCR.2014.07.015
P407
P50
P577
2014-09-08T00:00:00Z